報價延遲最少15分鐘:2026/06/10 19:03 EDT
盤後時段
|
||||
|
1.99 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.97
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.19/0.05
|
|
企業價值
166.47M
|
| 資產負債 |
|
每股賬面淨值
0.83
|
| 現金流量 |
|
現金流量率
0.10
|
| 損益表 |
|
收益
52.74M
|
|
每股收益
0.79
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel. |
